Iowa Medicaid Pharmaceutical and Therapeutics (P & T) Committee Meeting
September 13, 2007

Location: Iowa Medicaid Enterprise
100 Army Post Rd.
Des Moines, Iowa

Time: 9:30 a.m. – 4:30 p.m.

Final Agenda

1. Welcome & Introductions
   a) Committee Members and Staff
   b) Approval of the minutes

2. Update
   a) P & T Committee Chairperson and Vice Chairperson Elections
   b) Yearly review process of conflict of interest forms and confidentiality forms
   c) Legislation
   d) Preferred Drug List (PDL)
   e) Prior Authorization Criteria/Pro-DUR edits

3. Public Comment (See attachment 1 for Conflict of Interest Disclosure)

4. Closed Executive Session
   c) Economic Review of the Iowa Medicaid Preferred Drug List, Newly Released Drugs,
      Newly Released Generic Drugs, New Dosage Forms, and Contracts.
   d) Review and discussion of the confidential public comments
      *Lunch Break 12:30 a.m.-1:15 p.m.*

5. Preferred Drug List (PDL) discussion and deliberation
   (See attachment 2 for order of discussion)

6. Final Recommendations by the P & T Committee on the Iowa Medicaid Preferred Drug List

7. Review of Newly Released Drugs by Dr. Thomas Kline
   (See attachment 3 for order of discussion)

8. Final Recommendations by the P & T Committee on Newly Released Drugs (Open Session)

9. Review of Newly Released Generics drugs and New Dosage Forms and Strengths by Dr. Tom Kline
   (See attachment 4 for order of discussion)

10. Final Recommendations by the P & T Committee on Newly Released Generic Drugs and New Dosage Forms and Strengths (Open Session)

**Disclaimer: Executive Sessions may be necessary during the deliberation process**

For more information contact Sandy Pranger at spranger@ghsinc.com or (515) 725-127
The Iowa Medicaid Pharmaceutical and Therapeutics (P&T) Committee and persons testifying or presenting to the Iowa Medicaid P&T Committee are asked to disclose any financial or other affiliation with organizations that may have a direct or indirect interest in the business in front of the Committee.

A financial interest may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization.

An affiliation may include holding a position on an advisory committee or some other role or benefit to a supporting organization.

The existence of such relationships does not necessarily constitute a conflict of interest and will not preclude an individual from participating on, or addressing the P&T Committee. This policy is intended to openly identify any potential conflicts so that the P&T Committee members and the public are able to form their own judgments.

Please check the box of the statement that best applies.

- **Statement of No Conflicts**
  I do not have a current or recent (within the last 12 months) financial arrangement or affiliation with any organization that may have a direct interest in the business before the Iowa Medicaid P&T Committee.

- **Disclosures**
  I have a financial interest, affiliation or am employed by an organization that may have a direct interest in the business before the Iowa Medicaid P&T Committee

- **I refuse to state my affiliations**

<table>
<thead>
<tr>
<th>Organization</th>
<th>Role/Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(print name)

(signature) (date)
Attachment 2

Iowa Medicaid Preferred Drug List

Disclaimer: The Iowa P & T Committee reserves the right to re-evaluate all medications within the same therapeutic category as those on the agenda scheduled to be discussed for the PDL Review, New Drug Review, New Generic Drug Review, and New Dosage Forms Review and vote to change the PDL status of other medications currently on the PDL. It is the responsibility of the drug manufacturer to provide representation, if necessary, at the P & T Committee Meeting when a competitor’s product is on the agenda for discussion.

A. Changes to the Iowa Medicaid Preferred Drug List (PDL)

1. Carisoprodol recommend change status on the PDL to non-preferred as recommended by the DUR Commission

2. Fludrocortisone acetate recommend change status on the PDL to preferred because the brand name Florinef is soon to be discontinued

3. Omacor will be changing to the name Lovaza

4. Pemoline recommend to remove from the PDL as it is no longer being manufactured

5. Prosom will be removed from the PDL because the drug is to be discontinued

B. PDL Categories Recommendation for More Than One Preferred Drug Trials

1. GI-Digestive Enzymes – require 2 preferred drug trials
2. GI-Proton Pump Inhibitors – require 3 preferred drug trials
3. Migraine-SSA (5HT) Tablets – require 3 preferred drug trials
4. Muscle Relaxants – require 3 preferred drug trials
5. Sedative/Hypnotics-Non-Benzo – require 2 preferred drug trials
Attachment 3
Newly Released Drugs

Disclaimer: The Iowa P & T Committee reserves the right to re-evaluate all medications within the same therapeutic category as those on the agenda scheduled to be discussed for the PDL Review, New Drug Review, New Generic Drug Review, and New Dosage Forms Review and vote to change the PDL status of other medications currently on the PDL. It is the responsibility of the drug manufacturer to provide representation, if necessary, at the P & T Committee Meeting when a competitor’s product is on the agenda for discussion.

1. Altabax – Recommend status on PDL as non-preferred
2. AzaSite-Recommend status on PDL as non-preferred
3. Elestrin- Recommend status on PDL as non-preferred
4. Exforge-Recommend status on the PDL as non-preferred
5. Letairis- Recommend status on PDL as non-preferred
6. Lybrel- Recommend status on PDL as non-preferred
7. Pataday- Recommend status on PDL as preferred
8. Symbicort- Recommend status on PDL as non-preferred
9. Veramyst Nasal Spray- Recommend status on PDL as non-preferred
Disclaimer: The Iowa P & T Committee reserves the right to re-evaluate all medications within the same therapeutic category as those on the agenda scheduled to be discussed for the PDL Review, New Drug Review, New Generic Drug Review, and New Dosage Forms Review and vote to change the PDL status of other medications currently on the PDL. It is the responsibility of the drug manufacturer to provide representation, if necessary, at the P & T Committee Meeting when a competitor’s product is on the agenda for discussion.

### NEWLY RELEASED GENERIC DRUGS

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Brand Name/Status on PDL/RDL</th>
<th>PDL/RDL Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amlodipine/Benazepril</td>
<td>Lotrel/Preferred</td>
<td>Non-Preferred</td>
</tr>
<tr>
<td>Cefdinir</td>
<td>Omnicef/Preferred</td>
<td>Non-Preferred</td>
</tr>
<tr>
<td>Moexipril</td>
<td>Univasc/Non-Preferred</td>
<td>Non-Preferred</td>
</tr>
<tr>
<td>Terbinafine</td>
<td>Lamisil/Preferred</td>
<td>Non-Preferred</td>
</tr>
</tbody>
</table>

### NEW DOSAGE FORMS

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Brand Name/Status on PDL/RDL</th>
<th>PDL/RDL Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmicort Flexhaler</td>
<td>Pulmicort Turbuhaler/Preferred but no longer available</td>
<td>Non-Preferred</td>
</tr>
<tr>
<td>Seroquel XR</td>
<td>Seroquel/Recommended</td>
<td>Non-Recommended</td>
</tr>
</tbody>
</table>